New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 50 mg/ml - solution for infusion - 250 mg/5ml - active: ciclosporin 50 mg/ml excipient: ethanol polyoxyl 35 castor oil - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ciclosporin 50mg - soft gelatin capsule - 50 mg - active: ciclosporin 50mg excipient: ethyl lactate gelatin glycerol lecithin medium-chain triglycerides peg-40 castor oil polysorbate 20 purified water sorbitan oleate titanium dioxide - solid organ transplantation: - prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allergenic transplantations. - treatment of transplant rejection in patients previously receiving other immunosuppressive agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; ethanol; glycerol; titanium dioxide; peg-40 hydrogenated castor oil; gelatin; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celgene ltd - thalidomide - capsule - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan - oral tablet - 2mg

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; dl-alpha-tocopherol; ethanol; gelatin; corn glycerides; peg-40 hydrogenated castor oil; titanium dioxide; glycerol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - changes as described in the letter 23 december 1998 from b wall.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ciclosporin 50 mg - 50 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ciclosporin 50 mg/ml - 50 mg/ml

Israel - English - Ministry of Health

perrigo israel agencies ltd - melphalan - powder and solvent for solution for injection - melphalan 50 mg/vial - melphalan - melphalan - for the palliative treatment of multiple myeloma and for the palliation of non resectable epithelial cancer of the ovary.